Similar articles

• Cystic fibrosis gene therapy trials and tribulations.

  Zeitlin PL. Zeitlin PL. Mol Ther. 2000 Jan;1(1):5-6. doi: 10.1006/mthe.1999.0016. Mol Ther. 2000. PMID: 10933904 No abstract available.
• Partial correction of endogenous DeltaF508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing.

  Liu X, Jiang Q, Mansfield SG, Puttaraju M, Zhang Y, Zhou W, Cohn JA, Garcia-Blanco MA, Mitchell LG, Engelhardt JF. Liu X, et al. Nat Biotechnol. 2002 Jan;20(1):47-52. doi: 10.1038/nbt0102-47. Nat Biotechnol. 2002. PMID: 11753361
• [Protein repair therapy in cystic fibrosis].

  Clément A, Tamalet A, Fauroux B, Epaud R. Clément A, et al. Rev Prat. 2003 Jan 15;53(2):163-6. Rev Prat. 2003. PMID: 12664848 Review. French.
• Developmental paradigm for early features of cystic fibrosis.

  Larson JE, Cohen JC. Larson JE, et al. Pediatr Pulmonol. 2005 Nov;40(5):371-7. doi: 10.1002/ppul.20169. Pediatr Pulmonol. 2005. PMID: 15830387 Review.
• Qualitative and quantitative analysis of mRNA associated with four putative splicing mutations (621+3A-->G, 2751+2T-->A, 296+1G-->C, 1717-9T-->C-D565G) and one nonsense mutation (E822X) in the CFTR gene.

  Tzetis M, Efthymiadou A, Doudounakis S, Kanavakis E. Tzetis M, et al. Hum Genet. 2001 Dec;109(6):592-601. doi: 10.1007/s00439-001-0631-0. Epub 2001 Nov 6. Hum Genet. 2001. PMID: 11810271